Recent News

• 01.28.2026 - BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin
• 01.28.2026 - BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
• 01.12.2026 - BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026
• 01.12.2026 - BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
• 12.18.2025 - BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld
• 12.18.2025 - BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
• 12.09.2025 - Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs
• 12.09.2025 - BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Recent Filings

• 01.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.28.2026 - EX-99.1 EX-99.1
• 01.14.2026 - EX-99.1 EX-99.1
• 01.14.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.12.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.06.2026 - EX-99.1 EX-99.1
• 12.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.18.2025 - SC TO-T/A Tender offer statement by Third Party